相关临床试验
128
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1955
进行中（未招募）
5
3.9%
已完成
66
51.6%
Enrolling By Invitation
1
0.8%
尚未招募
10
7.8%
招募中
9
7.0%
终止
16
12.5%
Unknown
5
3.9%
撤回
16
12.5%
暂无批准数据
- University of Mississippi researchers developed sugar-coated nanoparticles that exploit cancer cells' glucose transporter overexpression to deliver chemotherapy drugs more effectively to triple-negative breast cancer. - The innovative approach could reduce side effects by selectively targeting cancer cells while sparing healthy tissue, addressing a critical need for this aggressive cancer subtype. - Mississippi shows particularly high rates of triple-negative breast cancer, with 37% of breast cancer patients treated at the University of Mississippi Medical Center between 2016-2023 having this subtype. - The delivery mechanism may have broader applications for other diseases that overexpress glucose transporters, including colon cancer, brain cancer, and fatty liver disease.
- The DETECT Hep C Trial, the largest pragmatic clinical trial of HCV screening in emergency departments to date, found that nontargeted screening identified significantly more new hepatitis C infections than targeted screening (relative risk 1.34, P=0.02). - Among 147,498 patient visits across three high-volume emergency departments, nontargeted screening resulted in 154 new HCV diagnoses compared to 115 diagnoses with targeted screening based on risk factors. - Despite improved detection rates, both screening approaches showed concerning gaps in the care continuum, with only 9.1% of nontargeted and 9.6% of targeted screening patients achieving sustained virologic response at 12 weeks. - The study highlights an urgent need for innovative HCV treatment models, as the substantial decrease from diagnosis to cure represents a critical healthcare delivery challenge.
